What Novo Nordisk’s disappointing trial results mean for the obesity drug market

Taking stock of the drug industry, from the lab to the medicine chest

December 20, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Novo Nordisk STAT+ | What Novo Nordisk's disappointing trial results mean for the obesity drug market New data on Novo's drug candidate CagriSema raise questions about the long-standing edge the company has held in the obesity drug market. By Elaine Chen Opinion: Gene therapy trials should emphasize transparency, not secrecy Two recent deaths in gene therapy trials demonstrate that the industry needs to take a new approach to data sharing. By Rafael Escandon and Arthur L. Caplan STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Sandy Huffaker for STAT STAT+ | Ionis wins FDA approval for a rare disease therapy that lowers triglycerides Ionis has long partnered with larger pharma firms to develop and market its products, but the company is commercializing Tryngolza on its own By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser